Soheil Meshinchi, MD, PhD, a world leader in developing novel approaches to treating acute myeloid leukemia (AML), has been ...

Blackstone Life Sciences ("BXLS") today announced a research and development funding agreement to advance the clinical ...

A new CRISPR-based tool that is directly used on patients' cancer cells can identify genes and regulatory elements driving ...

Aptevo Therapeutics Inc. (NASDAQ:APVO) shares plunged about 18% on Tuesday even after the company reported promising interim clinical results for its acute myeloid leukemia (AML) treatment candidate, ...

Blackstone Inc. (NYSE:BX) is one of the best cheap blue chip stocks to buy according to analysts. Blackstone Inc. (NYSE:BX) ...

The clinical-stage biotechnology company announced that mipletamig, combined with venetoclax and azacitidine, delivered an 86% clinical benefit rate in newly diagnosed acute myeloid leukemia patients ...

Blackstone Inc. (NYSE:BX) is one of the best undervalued stocks to invest in right now. Barclays cut the price target on ...

Frontline patient outcomes are making the case for mipletamig to enhance standard-of-care therapy alongside venetoclax + azacitidine SEATTLE, WA / ACCESS Newswire / March 10, 2026 / Aptevo ...

Frontline patient outcomes are making the case for mipletamig to enhance standard-of-care therapy alongside venetoclax + azacitidine SEATTLE, WA / ACCESS Newswire / March 10, 2026 / Aptevo Therapeutic ...

Rigel Pharmaceuticals maintains strong sales momentum across its three approved targeted therapies. Learn why RIGL stock is a Buy.

Selected as a C-Further program with up to $1.1 million in non-dilutive, aggregate payments to advance IND-enabling development, with potential for meaningful double-digit downstream commercial ...